Narrow-Moat Icons Faces Macroeconomic Challenges in Near Term; Positive Long-Term Outlook
Icon's balance sheet is sound, with its revenue cyclicality and operating leverage each possessing a medium rating. Icon has historically maintained a fairly conservative balance sheet, and it ended ...
manilatimes2d
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results
Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.
BMJ3d
Climate footprint of industry-sponsored in-human clinical trials: life cycle assessments of clinical trials spanning multiple phases and disease areas
Objective This study aims to calculate the global warming potential, in carbon dioxide (CO 2) equivalent emissions, from all in-scope activities involved in phase 1, 2, 3 and 4 clinical trials ...
How Trump’s Medical Research Cuts Would Hit Colleges and Hospitals in Every State
Changes to a key funding formula will reduce research grants at hospitals and universities by billions — and may discourage ...